PLL 001
Alternative Names: PLL-001; Poly-L-lysine conjugates with acetate, butyrate, lactate, propionateLatest Information Update: 07 Mar 2025
At a glance
- Originator PLL Therapeutics
- Class Acetates; Anti-inflammatories; Butyrates; Drug conjugates; Lactates; Neuroprotectants; Propionates; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple sclerosis
Highest Development Phases
- Clinical Phase Unknown Multiple sclerosis
- Preclinical Amyotrophic lateral sclerosis; Dysbiosis; Stroke
Most Recent Events
- 07 Mar 2025 PLL 001 is available for licensing as of 07 Mar 2025. https://www.pll-therapeutics.com/clinical-trials/pipe-line/
- 07 Mar 2025 PLL Therapeutics has patent protection for PLL 001 (PLL Therapeutics website, March 2025)
- 27 Dec 2024 Clinical trials in Multiple sclerosis (unspecified route) (PLL Therapeutics pipeline, December 2024)